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Alzheimer’s disease (AD) is ultimately linked to the amyloid precursor protein (APP).
However, current research reveals an important synaptic function of APP and APP-like
proteins (APLP1 and 2). In this context various neurotrophic and neuroprotective
functions have been reported for the APP proteolytic fragments sAPPα, sAPPβ and the
monomeric amyloid-beta peptide (Aβ). APP is a metalloprotein and binds copper and
zinc ions. Synaptic activity correlates with a release of these ions into the synaptic cleft
and dysregulation of their homeostasis is linked to different neurodegenerative diseases.
Metal binding to APP or its fragments affects its structure and its proteolytic cleavage
and therefore its physiological function at the synapse. Here, we summarize the current
data supporting this hypothesis and provide a model of how these different mechanisms
might be intertwined with each other.
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INTRODUCTION
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder and a severe burden of our aging
societies (Schaller et al., 2015). One pathological hallmark of AD is the formation of senile plaques
deposited in the brain concomitant with a massive decline of neuronal mass and therewith of
memory and cognitive abilities (Selkoe and Hardy, 2016). On the molecular level, the amyloid
precursor protein (APP) is fundamental to the pathology as the plaques predominantly consist
of its proteolytic breakdown product, which is the neurotoxic amyloid-beta peptide (Aβ; Selkoe,
2011; Haass et al., 2012). APP and the paralogous APP-like proteins (APLP1 and 2) are expressed
in various tissues (APLP1 only in the brain) and in alternative splice forms (Walsh et al., 2007;
Müller and Zheng, 2012) and are concentrated in the synapses of neurons. They are single-span
type I transmembrane proteins with a large extracellular domain (ectodomain) and a short
cytoplasmic tail APP intracellular domain (AICD; Coburger et al., 2014). APP is a prime example
for ectodomain shedding by α-, β-, or γ-secretases and for regulated intramembrane proteolysis
(RIP) by the γ-secretase complex (Thinakaran and Koo, 2008; Haass et al., 2012). In the first step,
the majority of the extracellular domain is shed off at distinct sites within the juxtamembraneous
domain by different proteases, involving ADAM10 and BACE. The resulting extracellular
cleavage products are released in form of soluble fragments, designated according to the cleavage
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site as sAPPα and sAPPβ, respectively (Brunholz et al.,
2012). More recently, an additional more N-terminally located
η–cleavage site was described, possibly mediated by cleavage
of MT5-MMP (Willem et al., 2015). This causes an even more
complex picture of APP processing, including besides sAPPη
different extracellularly released fragments, such as Aη–α or
Aη–β peptides. In fact, accumulating evidence suggests that
the APP processing is likely even more complex, as additional
cleavage sites within the Aβ domain by e.g., Meprin β have been
described (Bien et al., 2012). However, the different residual
carboxyl-terminal fragments (CTFs) are subsequently cleaved
by the γ-secretase complex, which causes in case of preceded
BACE1 shedding release of various Aβ peptides (Aβ1–36 to
Aβ1–43) and the AICD (Steiner et al., 2008). The regulation of
cleavage is a key event for both physiological and pathological
processes, whereby the pathophysiological relevance of all the
different peptides is yet not well understood, and depends on
the localization of APP, on post-translational modifications,
and on its oligomerization state (Kienlen-Campard et al., 2008;
Eggert et al., 2009; Haass et al., 2012; Muresan and Ladescu
Muresan, 2015; Winkler et al., 2015). APP is in equilibrium
between monomeric and dimeric species (Soba et al., 2005;
Isbert et al., 2012) and underlies a rapid turnover from the
cell surface into endosomal compartments, the presumed major
place of Aβ generation (Thinakaran and Koo, 2008; Haass et al.,
2012).
APP localization, oligomerization state and processing are
influenced by direct binding to copper and zinc ions (Acevedo
et al., 2011; Baumkötter et al., 2014; Mayer et al., 2014)
and dysregulation of copper and zinc homeostasis are an
apparent feature of neurodegenerative diseases, including AD.
However, as APP binds copper and zinc with affinities in
the nano and micro molar range, respectively, and as local
concentrations of copper and zinc can vary quiet a lot, it
appears reasonable that metal binding occurs only under certain
pathophysiological conditions. Here, we summarize recent
advances in the molecular details of copper and zinc binding
to APP and their potential impact on APP processing and their
potential role in the pathological as well as in the physiological
context.
APP AND ITS FRAGMENTS AS
METALLOPROTEINS
APP is a multi-domain membrane protein with a single
transmembrane domain (TMD) and several unstructured
regions (APP numbering in the following corresponds to
APP770, UniProtKB: P05067; Figure 1). The large extracellular
ectodomain (residues 18–699) is divided into the N-terminal
growth factor-like domain (GFLD, 18–123), the copper-binding
domain (CuBD, 124–189), an unstructured acidic domain
(AcD, 190–289), a Kunitz-type protease inhibitor (KPI) domain
with an Ox2 region (290–364, not present in neuronal
APP695 splice form), the E2 domain (365–575), and the
juxtamembrane region (JMR, 576–699). GFLD and CuBD form
a structural unit termed E1 domain. The JMR harbors the
sites for secretase cleavage during the process of ectodomain
shedding.
Metal binding is well documented to APP and to Aβ peptides
(Hesse et al., 1994; Talmard et al., 2007; Kong et al., 2008;
Dahms et al., 2012; Baumkötter et al., 2014). Copper binding
to APP has been first structurally characterized for the CuBD
(Barnham et al., 2003; Kong et al., 2007). Copper (II) binds
with high affinity (KD of 10 nM; note: binding constants to
copper and zinc ions strongly depend on the applied method
and conditions and values have to be evaluated critically) in a
slightly distorted square pyramidal geometry (a type 2 non-blue
site) to three protein ligands (His147, His151 and Tyr168) and
two water molecules (Figure 2A; Kong et al., 2008). The distorted
type 2 geometry is consistent with an observed redox-activity of
APP, and CuBD was found to also bind copper (I) (with one
water ligand lost) although no conformational change within the
protein could be detected. Interestingly, although not interpreted
in the original articles, a nearby disulfide bridge (Cys144-
Cys174) is partly reduced in the high-resolution structures.
The mechanism of how copper-binding to the CuBD could
FIGURE 1 | Schematic overview of amyloid precursor protein (APP770). The domain architecture is given with residues involved in metal binding and cleavage
sites of various secretases. The E1 domain contains two copper binding sites (orange lines) with clustered residues (four histidines and one tyrosine), one in the
growth factor like domain (GFLD, blue) and one in the copper binding domain (CuBD, green). The E1 domain is followed by an acidic domain (AcD) and a Kunitz
protease inhibitor (KPI) domain (gray). The E2 domain (yellow) binds copper via four histidine residues (orange lines). Zinc binding involves three residues of the
copper binding site (His457, His507 and His511, while His388 is replaced by a water molecule). The residues corresponding to the recently identified zinc binding
site in APLP1 are highlighted in blue. Three of four histidines are conserved while His450 is replaced by Met531 in APP770. The juxtamembrane region (JMR) and
transmembrane domain (TMD, gray) harbor the Aβ region (red). After β-secretase cleavage at Met671 and further γ-secretase cleavage at various sites within the
TMD, Aβ is liberated into the extracellular space, whereas the APP intracellular domain (AICD) is released into the cytosol. Cleavage by α-secretases occurs within
the Aβ region at Lys687. Additionally, η-secretase cleaves the ectodomain at position Asn579.
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FIGURE 2 | Metal binding to the E1 domain. (A) The CuBD of human APP bound to copper (II) (PDB code: 2fk1). Copper is coordinated by three protein ligands
and two water molecules. The shown disulfide bridge is partially reduced. (B) The GFLD of human APP bound to copper (II) (PDB code: 4jfn). Copper is coordinated
in the same geometry as in the CuBD. Two ligand sites are occupied by protein and three sites by a crystal contact (aspartate) replacing three water molecules. The
inferred hydrated state in solution is shown. The disulfide bridge adjacent to the copper binding site is reduced. (C) A putative “closed” E1 domain by the
intramolecular combination of the two ligand bindings sites of GFLD and CuBD and modeling of a flexible linker (yellow). (D) The respective “open” E1 domain by
intermolecular combination of the binding sites. The monomeric E1 domain corresponds to PDB code 4pwq.
decrease Aβ production as described in CHO cells (Borchardt
et al., 1999) and various mouse studies (Bayer et al., 2003)
however remained enigmatic. Specific binding of zinc to two
C-terminal cysteines (Cys186 and Cys187) within the CuBD
has also been reported (Bush et al., 1993). However, data
had been acquired with tryptic and synthetic peptides and in
available structures the two cysteines are not available for zinc
coordination. Crystallographic analyses of the CuBD with bound
zinc would help to clarify this point and would build the basis for
follow-up studies, addressing the impact of zinc binding on APP
pathophysiology.
Recently, we reported specific copper binding to the
N-terminal GFLD (Figure 2B; Baumkötter et al., 2014). Here,
copper (II) was found to adopt the same ligand geometry with
however two protein ligands (His108 and His110) in a flexible
hairpin loop also involved in Heparin binding and putatively
three water ligands (mimicked in the crystal by an aspartate
of a symmetry contact). Binding affinity as determined by
isothermal titration calorimetry (ITC) is in the low nanomolar
range (KD of 28 nM) almost as high as to CuBD. Copper-
binding to the GFLD again correlates with the reduction of a
neighboring disulfide bridge (Cys98-Cys105) pointing to redox-
activity also of this site. Furthermore, the match of geometry
and functionality is suggestive for a complementation of the two
copper-binding sites by either a conformational change within
the E1 domain into a ‘‘closed’’ conformation (Figure 2C) or by
dimerization of two ‘‘open’’ E1 domains in trans (Figure 2D). In
line, conformational flexibility within the E1 domain has been
validated recently (Hoefgen et al., 2015). In contrast to the CuBD
and E2 domains, no binding to the GFLD could be detected for
zinc ions (Baumkötter et al., 2014).
The E2 domain (Dahms et al., 2012), which like E1 binds
strongly to copper (KD of 13 nM) and with low affinity to
zinc (KD of 3.9 µM; with some uncertainties of the ITC
measurements) harbors two or three different metal binding
sites, here designated as M1–3 (also see Table 1). Both metals
bind to the same evolutionary conserved site (denoted as M1)
within the APP family and due to the more than 100 times
lower affinity, zinc (II) cannot compete for copper (II) binding
in vitro. In X-ray structures of the metal-bound E2 domain the
M1 site is found central to the coiled-coil like fold and consists
of four histidines (His388, His457, His507 and His511 for
APP770 numbering) spread on three helices (αB, αC and αD;
Figures 3A,B; Dahms et al., 2012). The ligand coordination
has been described as tetrahedrally-distorted square planar
geometry (although a fifth ligand is missing here compared
to the E1 copper binding sites). Notably, in contrast to the
GFLD and CuBD, no redox-activity has been observed for the
M1 site. The central location of the M1 site enables a metal
dependent conformational switch within the E2 domain with
a 12◦ bending of the helical rod (Figure 3C) and bending
correlates with an increased rigidity and thermostability of the
E2 domain.
Copper binding to the E2 domain was reported to stimulate
heparin binding, which might be of physiological importance
by modulating APP binding to the extracellular matrix during
brain development (Dienemann et al., 2015). However, in an
X-ray structure of dimeric human APLP1 E2 domain bound
to a heparin-hexasaccharide, the M1 site is destroyed and the
four histidines are involved in carbohydrate binding instead (Lee
et al., 2011). Here, the E2 domain is bent in an orthogonal
direction by 13◦ due to dimer formation that allows the
accommodation of the ligand in the dimer interface in a
2:1 protein to ligand ratio (Figure 3D).
Binding to the M2 site within the E2 domain has been
analyzed by competitive cadmium displacement studies similar
to analysis of M1 (Dahms et al., 2012). Thereby, cadmium was
only partially replaced by zinc, but not by copper. However, no
further functional studies validated its functional or structural
relevance yet.
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TABLE 1 | Metal binding properties of amyloid precursor protein (APP)/APP-like proteins (APLPs).
Metal binding site properties Alteration in
structure
Validated by
mutations
Functional
implications
APP APLP1 APLP2 Cu Zn ITCa X-rayb
E1 GFLD H108 H130c - X × Yes
KD: 28 nM1
ratio: 1:11
Yes1 minor; reduction of
disulfide bridge in
LBL1
Yes (ITC, Co-IP,
cellular assay)1
Cu stimulates cis
and trans directed
dimerization1
H110 H132 -
CuBD H147 - H163 X × Yes
KD: 10 nM2
ratio: 1:11
Yes3 no change
H151 H174 H167
Y168 - Y184
E2 M1 H388 H307 H387 X X Yes
Cu: KD: 13 nM
ratio: 1:1
Zn: KD = 4 µM
ratio: 1:14
Yes4 Distinct changes,
bending of
N-terminal coiled
coil by 12◦4
Yes (ITC)5 Cu and Zn
stimulate binding of
heparin5,
involvement of M1,
M2 is unclear
H457 H376 H456
H507 H426 H506
H511 H430 H510
M2 E462 - E461 × (X) No
D504 - D503
H533 H452 H532
M3d H511 H430 H510 × X n.d. n.d. n.d. Yes (FRET)6 Minor
impact of single
mutants
Zn stimulates
homotypic
trans-dimerization6
H514 H433 H513
- H450 -
H533 H452 H532
a Isothermal titration calorimetry; bX-ray crystallography; camino acids indicated in gray represent conserved positions w/o experimental data validating copper or zinc
binding; dreported APLP1 specific Zn binding site, here designated as M3 site. 1Baumkötter et al. (2014), 2Hesse et al. (1994), 3Kong et al. (2007), 4Dahms et al. (2012),
5Dienemann et al. (2015) and 6Mayer et al. (2014)
FIGURE 3 | Metal binding to the E2 domain. (A) The copper (II) binding site in the center of the coiled-coil like human E2 domain (PDB code: 3UMK). The four
histidine ligands are spread on three different helices. (B) Structure of the complete human E2 domain bound to copper (II). (C) Superposition of E2-Cu(II) with the
respective apo form (PDB code: 3NYJ) highlighting the metal induced conformational change. (D) Superposition of E2-Cu(II) with a dimeric APLP1 E2 domain in
complex with a heparin hexa-saccharide (PDB code: 3qmk). Heparin binds in a 1:2 molar ratio and occupies the copper (II) binding site.
Two other more recent studies suggested a zinc binding site
in the APLP1 E2 domain (between M1 and M2 of APP E2:
APLP1 residues His430, His433, His450 and His452) to regulate
homo- and hetero-dimerization with APP and APLP2 (Mayer
et al., 2014, 2016). Notably, only three of the four histidine
residues involved in binding are conserved in APP and APLP2
(Table 1). However, as mutations of single histidine residues
only had a minor impact on APLP1 cell adhesion features, it
appears reasonable to postulate that binding of zinc to theM3 site
might affect APP and APLP2 function in a similar manner.
Moreover, specific dimerization implies complementation of
metal coordination in trans, which would require a different
dimerization as observed in the X-ray structure with heparin.
Such zinc mediated dimerization was observed in a crystal
contact of another recent APLP1 E2 structure bound to a heparin
dodecasaccharide (Dahms et al., 2015), which however, was
mediated again by other surface exposed histidines. Therefore,
the structural and physiological consequences of copper and zinc
binding to the E2 domain appear still highly controversial and
need further investigations.
Since copper and zinc binding to APP is predominantly
mediated by histidine and due to pKa values of this amino
acid, the interaction of APP with copper and zinc is impossible
under acidic conditions. APP is trafficked through the secretory
pathway to the cell surface up to endosomes and lysosomes.
Thereby it passes cell compartments with different pH values.
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FIGURE 4 | Metal binding to the Aβ peptide. (A) The proposed copper (II) coordination by the N-terminus of Aβ and two histidines. The model corresponds to
copper (II) coordination found in the crystal structure of GFLD-Cu(II) with the aspartate originating from a crystal contact (PDB code: 4jfn). (B) NMR structure of
dimeric human Aβ (1–16) bound to zinc (II) (PDB code: 2mgt). The zinc ion mediates dimerization via coordination of equivalent residues. (C) NMR structure of
dimeric rat Aβ (1–16) bound to zinc (II) (PDB code: 2li9). Dimerization via the zinc ion is different and highlights the conformational flexibility of Aβ peptides.
The pH of the ER is near neutral, while the downstream
compartments (cis-and trans-Golgi, secretory vesicles) become
progressively more acidic down to pH 6 in the trans-Golgi
and <5 in lysosomes (Casey et al., 2010). Thus, it is likely
that APP binding to copper and zinc varies between different
subcellular compartments, possibly altering its structure and
binding properties. In line with this, it was reported that APP
can adopt different conformations depending on pH (Hoefgen
et al., 2015). Interestingly, the altered structure at acidic pH is
stabilized by hydrogen bonds involving His147 and Tyr168 in
the CuBD that mediate copper binding under neutral pH
conditions.
Most attention has been given to copper and zinc binding
to Aβ peptides due to the direct influence on pathological
processes and metal accumulation (millimolar range) in the
amyloid plaques (for review see Tõugu et al., 2011; Tiiman et al.,
2013). From a structural viewpoint, the peptide-ligand complexes
are difficult to tackle, as both metals rapidly precipitate Aβ
and induce a multitude of Aβ conformations and oligomeric
assemblies. Furthermore, Aβ conformations strongly depend
on the conditions (e.g., pH and solvent) used for structure
determination. The role of metal ions in the self-assembly of
Aβ has been reviewed in detail recently (Faller et al., 2013).
In consensus, copper and zinc bind to the N-terminus of
Aβ(1–16; numbering for Aβ-peptide only) in a 1:1 ratio mostly
involving the aspartate and alanine at the very N-terminus
(Asp672 or Asp1 in Aβ nomenclature, and Ala673), glutamate
11, and various histidines (His6, His13 and His14). Furthermore,
redox-active copper is able to induce reactive oxygen species
(ROS) that lead e.g., to aggregation-prone cross-linked Aβ
dimers by oxidization of Tyr10 (Smith et al., 2007). Respective
residues 1–10 are missing in APLP1 and also APLP2 has a
two-residue deletion including His6. Affinities for copper vary
significantly between attomolar andmicromolar values, although
careful analyses suggest values in the range of 30–60 nM
(Tõugu et al., 2011; Tiiman et al., 2013). No X-ray or NMR
structure has been reported for an Aβ-copper complex. At
a physiological pH of 7.4 a square-pyramidal coordination
is assumed including Asp1 and His6 and His13 or His14
(Faller et al., 2013). Interestingly, this coordination is exactly
as found for the X-ray structure of the GFLD-Cu(II) complex,
which might therefore be regarded as first atomic model of
an Aβ-Cu(II) complex (Figure 4A). Ligands might originate
from the same or different Aβ peptides, which reflects the
ability of copper (II) to bind to all forms of monomeric,
fibrillary and non-fibrillary Aβ species. Zinc binds to the same
site as copper, but binding is again weaker with affinities
in the lower micromolar range. The commonly accepted
coordination includes Asp1, Glu11 and the three histidines.
Zinc immediately precipitates Aβ and NMR structures are
deposited only for zinc-mediated dimeric Aβ-zinc (II) species
of a mutant human Aβ(1–16) and rat Aβ(1–16) revealing
part of this coordination and different dimerization patterns
(Figures 4B,C). Aggregation increases the affinity of Aβ for
copper and zinc leading to the apparent high concentrations
in the amyloids. However, the structural understanding of
this process is just at the beginning despite all efforts
taken.
In summary, the biometals copper and zinc bind to different
folded regions of the APP ectodomain and to various Aβ
species. Affinities for all sites are about 100 times higher for
copper, which challenges the idea of zinc binding to APP
in the synaptic cleft despite its excess. In all complexes the
metals seem to be involved in diverse conformational changes
of APP and APLP1 as well as APLP2, inducing dimerization
or oligomerization in different ways and thus might influence
specific physiological and pathological processes.
THE ROLE OF COPPER AND ZINC IONS IN
ALZHEIMER’S DISEASE
Zinc and Alzheimer’s Disease
Sustained elevation of zinc levels are detrimental for neurons and
have therefore been implicated in AD pathogenesis (Koh et al.,
1996). A multitude of studies have analyzed overall zinc levels
within AD vs. control brains with rather inconsistent outcome
(Ayton et al., 2013). In consensus, however, it has been clearly
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demonstrated that zinc levels are increased in amyloid plaques
of AD patients (Bush et al., 1994c). The elevated zinc levels
concern only a small fraction of the total cortical volume, and
the total tissue zinc concentrations only rise during advanced
pathology (Religa et al., 2006). Closer analysis revealed zinc
binding to the residues 6–28 of the Aβ peptide (Bush et al.,
1993, 1994a,b,c), where zinc ions may bind to histidines 6,
13 and 14 (Damante et al., 2009) as described above. Binding
of zinc ions induces rapid precipitation of Aβ into insoluble
aggregates in humans. However, since the rat and mouse Aβ
sequences differ from the human Aβ sequence in three amino
acids, differences in the affinity for zinc binding may explain why
mice and rats do not develop amyloid pathology (Bush et al.,
1994c). Zinc is released by glutamatergic fibers in the cortex and
hippocampus where the synaptic vesicle located zinc-transporter
3 (ZnT3) loads the metal into synaptic vesicles (Frederickson
et al., 2000). In addition to the increased zinc concentrations
in amyloid plaques the expression of ZnT3 is closely associated
to Aβ deposition. Ten different zinc-transporters have been
identified with ZnT3 showing its highest expression within
the brain (Palmiter et al., 1996; Huang and Tepaamorndech,
2013). Low ZnT3 expression reduces interstitial (Lee J.-Y.
et al., 2002) and vessel-wall (Friedlich et al., 2004) amyloid
but increases the levels of soluble Aβ in the brains of the
APP transgenic x ZnT3 KO mice (Lee J.-Y. et al., 2002). Zinc
does not only affect Aβ aggregation but also influences APP
processing and function. APP processing and subsequent Aβ
generation is dependent onADAM10 activity. ADAM10 requires
zinc binding for proteolysis and therefore subtle changes in
ADAM10 activity influence Aβ production (Lammich et al.,
1999).
Copper and Alzheimer’s Disease
In healthy brain tissue the total copper levels have been reported
to increase from youth to adulthood followed by a constant
decrease during aging (Maynard et al., 2002). Aged but healthy
brain tissue contains approximately 80 µM copper, whereas
copper levels are decreased by approx. 30%–40% in affected
brain regions of AD patients (Deibel et al., 1996; Adlard and
Bush, 2006; Religa et al., 2006; Magaki et al., 2007). In contrast,
copper levels (and zinc levels) are enriched in extracellular
amyloid plaques (Lovell et al., 1998; Dong et al., 2003; Miller
et al., 2006; Leskovjan et al., 2009). Thus, either elevated levels
of copper directly associated with the Aβ peptide or decreased
levels of copper in amyloid plaques surrounding brain tissue
might affect the course of AD. Copper binds with high affinity
to Aβ and promotes its oligomerization and neurotoxicity
(Atwood et al., 1998, 2004; Huang et al., 1999; Masters and
Selkoe, 2012). Moreover, cellular copper deficiency promotes
the amyloidogenic processing of APP leading to increased Aβ
levels (Cater et al., 2008; Hung et al., 2009), whereas an elevation
of intracellular copper levels promotes the non-amyloidogenic
pathway and attenuates Aβ generation in cells (Borchardt
et al., 1999; White et al., 2006; Donnelly et al., 2008) as
well as in transgenic mice (Cherny et al., 2001; Bayer et al.,
2003; Phinney et al., 2003; Adlard et al., 2008). However, the
molecular mechanisms leading to elevated Aβ production in
the presence of decreased cellular copper levels are currently
elusive.
It has been suggested that copper induces conformational
changes in APP that influence the monomer/dimer equilibrium
and thus affects the proteolytic processing of APP (Kong et al.,
2008; Baumkötter et al., 2014). In line, it has been shown that
enhanced APP dimerization leads to reduced Aβ generation
(Kienlen-Campard et al., 2008; Eggert et al., 2009). On the other
hand, it has been reported that attenuated APP dimerization
correlates with reduced Aβ levels (Munter et al., 2007; Kaden
et al., 2008; Richter et al., 2010). Further studies will be required
to solve this discrepancy.
An alternativemechanism underlying elevated Aβ production
in the presence of decreased cellular copper levels might concern
the influence of copper on APP trafficking (Hung et al.,
2009; Acevedo et al., 2011), either by altered conformational
changes (Spoerri et al., 2012) or more indirectly by regulation
of APP phosphorylation (Acevedo et al., 2014). Additionally,
copper modifies Aβ and accelerates its aggregation. The copper-
induced Aβ oligomerization was found to contain a membrane-
penetrating structure (Curtain et al., 2001; Smith et al., 2006).
As for other Aβ aggregates, the copper-bound Aβ oligomers
complex have been shown to exhibit cytotoxic properties and vice
versa general Aβ toxicity in tissue culture is partially dependent
on copper (You et al., 2012).
Since more than a decade it is known, that copper may
play also a detrimental role in AD due to its interaction with
Aβ-peptides leading to amyloid fibrilization, its influence on
Tau and GSK3β and induction of oxidative stress (Kenche
and Barnham, 2011). Based on these observations Bush and
Tanzi (2008) have proposed the ‘‘Metal Hypothesis of AD’’.
Therefore potential therapeutic strategies have been developed
either targeting Aβ copper interactions by selectively occupying
the metal binding site on Aβ or through development
of peptides effectively competing with Aβ-peptides for the
metal ions. Such an approach has been developed e.g. for
Wilson’s disease (WD) to target a metal overload using metal
chelators. Such chelators as desferrioxime, penicillamine and
trientine have very high metal binding affinities and are
hydrophilic. Therefore such chelators are inappropriate to
tackle a brain disease like AD since they will not be able
to cross the blood brain barrier (BBB). In contrast to these
hydrophilic compounds metal protein attenuating compounds
have been developed like clioquinol (CQ, 5-chloro-7-iodo-8-
hydroxyquinoline), which are indeed capable to cross the BBB.
Although some approaches have been promising in early clinical
trials none of these compounds have clinically proven to be
effective in AD (Adlard et al., 2008; Lannfelt et al., 2008).
One potential drawback might be the unwanted side effects
on APP copper interactions and its subsequent physiological
consequences.
COPPER AND ZINC IN THE INTERPLAY
WITH APP AT THE SYNAPSE
Based on the observation that zinc and copper bind APP,
APLP1 and APLP2 with high affinities and the high abundance
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of these metals in the synaptic cleft during neurotransmission,
the impact of copper and zinc on the trans-cellular dimerization
properties of APP during cell adhesion and synaptogenesis went
into focus of current research.
Influence of Copper on Brain Function
The transition state metals copper and zinc, as well as iron,
are essential for the catalytic activity of a variety of enzymes,
including amongst others the cuproenzymes cytochrome c
oxidase, superoxide dismutase (SOD), ceruloplasmin, tyrosinase
and dopamine β hydroxylase (Turski and Thiele, 2009).
However, copper is also toxic to cells and thus, its distribution
in the cell has to be tightly regulated. In neurons, the copper
transporter 1 (CTR1) mediates copper import (Lutsenko et al.,
2010). Interestingly, only reduced copper (I) is transported by
CTR1 (Macreadie, 2008). Thus, extracellular copper (II) has to
be reduced to copper (I) by membrane bound metalloreductases
prior to uptake into the cell by CTR1. The assumed mammalian
metalloreductase remains to be identified (Lee J. et al., 2002).
Potential candidates are the Steap proteins (Ohgami et al., 2006)
as well as APP since it binds with high affinity to copper and
is also able to reduce copper (Multhaup et al., 1996). However,
elevated APP levels cause a decrease and APP depletion an
increase of intracellular copper concentrations (White et al.,
1999; Maynard et al., 2002, 2006; Phinney et al., 2003; Bellingham
et al., 2004; Treiber et al., 2004), arguing against a function of
APP in copper influx.
Copper imported via CTR1 is delivered by specific copper
chaperones directly to different cuproenzymes. For example,
the copper chaperone CCS mediates transfer of copper from
CTR1 to the SOD (McCord and Fridovich, 1969; Culotta
et al., 1997). Delivery of copper to cuproenzymes in the
secretory pathway is mediated by the copper chaperone
ATOX1, which transfers copper (I) from CTR1 to the
intracellular copper transporters ATP7A and ATP7B, located
in different intracellular compartments (Kim et al., 2008).
Besides these principal metallochaperone mediated copper
transport pathways, cytoplasmic copper also binds to glutathione
immediately after entry into the cell and is subsequently
transferred to metallothionein (Hung et al., 2010). Due to the
described mechanisms, the intracellular concentration of free
copper is maintained at exceedingly low levels (Rae et al.,
1999).
Copper is found all over the brain and is most abundant in the
basal ganglia (Madsen and Gitlin, 2007). The data on chelatable
copper concentrations in extracellular fluids and intracellular
compartments is a matter of debate. In some particular neurons
copper is released at the synapse (Hartter and Barnea, 1988;
Brown et al., 1997), estimated to reach upon depolarization and
activation of N-methyl-D-aspartate (NMDA) receptors (Rajan
et al., 1976; Hartter and Barnea, 1988; Kardos et al., 1989;
Peters et al., 2011; Tamano and Takeda, 2011) micromolar
concentrations (Kardos et al., 1989) to approx. 15 µM (Hopt
et al., 2003). Moreover, transient copper concentrations above
100 µM at the synaptic cleft have been reported (Kardos
et al., 1989; Gaier et al., 2013). Consistently, the synaptic
cleft is the only reported microenvironment within the brain
where chelatable copper might be easily excessible (Roberts
et al., 2012). Interestingly, the activation of NMDA receptors
leads to relocalization of ATP7A from the trans golgi-network
(TGN) to neuronal processes and thus in turn contributes to
increased copper concentrations at the synapse (Schlief et al.,
2005).
Loss-of-function mutations in copper transporters, such as
ATP7A and ATP7B, lead to hereditary diseases, Menkes disease
(MD), or WD. Loss of ATP7A function causes growth failure,
brittle hair, hypopigmentation, arterial tortuosity and neuronal
loss most prominent in the hippocampus and cerebellum (Okeda
et al., 1991; Chelly et al., 1993; Mercer et al., 1993; Vulpe
et al., 1993). The phenotypes are mostly due to consequences
of specific cuproenzymes dysfunction resulting from reduced
cellular copper levels (D’Ambrosi and Rossi, 2015). Loss of
ATP7B, which is primarily expressed in the liver, leads to copper
overload in the liver and later in the brain, possibly due to
impaired copper transport at the BBB (Huster and Lutsenko,
2007; Kaler, 2011). Although copper levels are mainly increased
in cerebrospinal fluid and in the basal ganglia (Südmeyer
et al., 2006), WD patients show widespread neuronal cell
loss and white matter abnormalities, causing symptoms that
include parkinsonism, seizures and mental disorders (Gitlin,
2003).
The molecular mechanisms underlying copper induced
neurodegeneration are only partially understood. Mechanism(s)
discussed involve S-nitrosylation, oxidation and allosteric
modulation, increased anchorage of the neurotransmitter
receptors to the membrane, and modulation of neurotransmitter
receptor function (Weiser and Wienrich, 1996; Kim and
Macdonald, 2003; Schlief and Gitlin, 2006; El Meskini et al., 2007;
Huidobro-Toro et al., 2008; Peters et al., 2011; Gaier et al., 2013).
Influence of Zinc on Brain Function
In contrast to copper ions there is a substantial amount of
zinc loosely bound to biomolecules, designated as reactive
or chelatable zinc, which is implicated in neuronal signaling.
Reactive zinc is largely distributed within presynaptic vesicles
in some axon terminals throughout the telencephalon and
co-localizes with a subset of glutamatergic neurons (Frederickson
et al., 2000). Cytosolic reactive zinc levels are in the picomolar
range and are estimated to rise to micromolar levels in the
synaptic cleft and in intracellular compartments, such as
mitochondria, secretory vesicles and lysosomes (Sensi et al.,
2009). While it is evident that zinc is released during synaptic
activity, there is little consensus on the amount or duration
of its existence in the synaptic cleft (Watt et al., 2010). Zinc
homeostasis is mainly maintained by regulated activities of
‘‘zinc importing’’ ZnT transporters (SLC30 family), ‘‘zinc
exporting’’ ZIP transporters (SLC39 family), and zinc buffering
proteins, including metallothioneins (Sensi et al., 2011). At
the synapse, vesicular released zinc interacts with various
neuronal ion channels (NMDA, (α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid, AMPA), GABAA (γ-aminobutyric
acid type A) receptors), Glycine and other surface receptors,
such as TrkB. Furthermore, zinc can bind to and regulate
ProSAPs/Shanks scaffolding proteins of the postsynaptic
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density (PSD), involved in synaptic signaling. Indeed, in
some cerebral areas nearly 50% of the glutamatergic synapses
are actually ‘‘glu-zinc-ergic’’ (Watt et al., 2010). Therefore,
zinc is considered as an important synaptic modulator,
affecting neurotransmission at inhibitory as well as excitatory
synapses.
Influence of Copper/Zinc on APP Synaptic
Function
Synaptic function of APP is discussed in detail in other
chapters of this special issue. Briefly, loss of APP function
leads to a reduced number of dendritic spines (Watt et al.,
2010; Tyan et al., 2012) and to impairments in the structural
plasticity (Zou et al., 2016). A possible mechanism infers an
important trans-synaptic adhesion molecules like function for
membrane anchored APP (Siddiqui and Craig, 2011) and major
neurotrophic roles of the secreted sAPPα ectodomain (Soba
et al., 2005; Bell et al., 2008; Jimenez et al., 2011; Aydin et al.,
2012; Caldwell et al., 2013; Baumkötter et al., 2014). Loss of
APLP2 (von Koch et al., 1997) had no consequences on brain
function (Weyer et al., 2011, 2014; Midthune et al., 2012),
whereas APP/APLP2 andAPLP1/APLP2 double KOmice exhibit
severe deficits in formation of the neuromuscular junction
and die early after birth. This suggests that APP/APLPs share
some overlapping functions, but also have distinct synaptic
functions that are not compensated by the other family
members.
As pointed out before, copper binds APP at different sites
within the E1 and E2 domain, causing structural changes
and altered dimerization properties and heparin binding
characteristics (Baumkötter et al., 2012). Copper binding to the
GFLD coincides with structural rearrangements in the heparin-
binding loop region (Baumkötter et al., 2014), possibly also
representing an APP dimerization interface (Kaden et al., 2008).
In line, copper-induced trans-directed in vitro interaction of
APP, and mutations, abolishing copper-binding to the GFLD,
reduce APP synaptogenic activity in a cellular assay system
(Baumkötter et al., 2014). Therefore, it appears reasonable
that copper might also modulate the neurotrophic function of
secreted APP forms. Thus, copper modulation in the synaptic
cleft upon synaptic activity might contribute to APP trans-
synaptic signaling in context of synaptic maturation (Figure 5).
Actually, a decrease of D-serine in brains of APP knockout
mice was reported to contribute to synaptic deficits in aged
mice (Zou et al., 2016). Most likely the decrease in D-serine
is explained by a loss of function of APP in calcium-
dependent release of D-serine from astrocytes (Martineau
et al., 2014). Thus, as both D-serine and zinc can bind and
modulate NMDA receptor function in antagonistic ways, it is
tempting to speculate that APP might sense changes in zinc
concentrations that in turn could affect D-serine secretion in
the synaptic cleft, antagonizing the antidepressant-like effects
of zinc and thereby contributes to homeostasis of synaptic
activity. A validation of this tempting hypothesis is however
hampered by the technical limitation for the quantification
of reactive copper in the synaptic cleft. Knock-in approaches
testing different APP mutants might be a way to disentangle
FIGURE 5 | Interplay of synaptic copper, zinc and APP/APLPs. Scheme
showing postsynaptic copper and presynaptic zinc release by ATP7A and
zinc-transporter 3 (ZnT3), respectively. APP/APLPs (here indicated as APP)
either form trans-synaptic dimers or are secreted into the synaptic cleft. APP
processing, APP trans-dimerization, and possibly also binding of sAPP to a
putative receptor are modulated by copper and zinc levels. As release of these
metal ions depends on synaptic activity, structural changes within APP/APLPs
might be accompanied with copper and zinc binding. Concomitantly, metal
binding seems to function as a sensor to strengthen or destabilize APP
oligomers. At glutamatergic synapses a key player in this process is the
N-methyl-D-aspartate (NMDA) receptor, with both sAPP and zinc affecting
NMDAR function. In addition, the loss of APP goes along with a decrease in
D-Serine, which acts as a co-agonist on NMDAR. The mechanism underlying
altered D-Serine secretion has not yet been determined.
the functional relation between copper and APP at the
synapse.
Different reports suggest binding of APP, APLP1 and to
a minor extent also APLP2 to zinc with affinities in the low
micromolar range (Bush et al., 1993; Mayer et al., 2014, 2016)
and it was shown by FRET analysis of heterologous expressed
APP/APLPs that addition of zinc can induce clustering of
APP, APLP1 (EC50: 10 µM), and APLP2 (EC50: 300 µM) as
well as of all types of heterotypic APP/APLPs combinations
(Mayer et al., 2016). Interestingly, combinations of APLP1 with
APLP2 also exhibited an EC50 at about 50 µM. As reactive
zinc concentrations can reach high micromolar and possibly
also millimolar concentrations in the synaptic cleft, all types of
oligomers (including homo- and heterotypic APLP2 containing
oligomers) are likely formed also under in vivo conditions
at the synapse. Consistently, addition of 50 µM zinc to cells
expressing APLP1 caused a lateral concentration at cell-cell
contact sites (Mayer et al., 2016), as formerly described by Soba
et al. (2005) in presence of copper (Baumkötter et al., 2014).
Notably, alanine mutations of one of four histidines involved
in zinc binding at the M3 site (H430/H433/H450/H452) did
not abolish zinc-induced oligomerization and only lowered the
affinity about two fold. This suggests that APP and APLP2 trans-
directed dimerization might also be affected by zinc in a similar
way, possibly in interplay with heparin binding and APP/APLPs
dimerization/oligomerization (Bush et al., 1994a).
Despite somemajor gaps in our understanding of APP/APLPs
synaptic function, the current data as presented in this review
article strongly suggest that activity-dependent changes in zinc
and copper concentrations in the synaptic cleft can be sensed
by the APP/APLP family. In turn, they seem to modulate
neurotransmission by different pathways including neurotrophic
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activity of sAPPα or trans-cellular dimerization/signaling.
However, one major gap in our current understanding, especially
in respect to the function of copper, is the limitation of available
sensitive sensors, allowing determination of local transient
changes in copper concentration. In this regard, live-cell optical
imaging with fluorescent sensors offers a potentially powerful
approach for interrogating aspects of labile copper accumulation,
speciation, trafficking, and redox function in living systems at
the molecular level. Such reagents have greatly facilitated the
study of calcium and zinc in cell biology, but analogs tools
for cellular copper remain underdeveloped (Zeng et al., 2006;
Dean et al., 2012). Therefore, the most promising way might
actually be, to use mutant APP impaired in copper and/or zinc
binding in different cellular assays, allowing to estimate the
pathophysiological impact of copper and zinc on APP function
and its role in AD.
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